Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study

Table 2

Comparison of laboratory investigation findings in CHC patients and healthy controls.

Lab. parameters	Before	After	Control	P value
Total bilirubin (mg/dl)				0.144994
Mean ±SD	0.77±0.37	0.59±0.30	0.72±0.71
Median (range)	0.7(0.3-1.7)	0.5(0.2-1.4)	0.45(0.25-1.3)
Albumin (g/dl)				< 0.00001
Mean ±SD	3.82±0.31	4.33±0.44	4.46±0.42
Median (range)	4(3.1- 4.5)	4(4-5)	4.4(4-5)
Total protein (g/dl)				0.156156
Mean ±SD	7.51±0.56	7.86±0.71	7.28±0.99
Median (range)	7.6(6.6-8.5)	7.9(6.2-9.8)	7.4(6.3-7.9)
ALT (IU/L)				0.00001
Mean ±SD	46.23±25.82	18.56±10.59	21±5.66
Median (range)	34(14-94)	15.5(6-56)	19(4-37)
AST (IU/L)				0.00001
Mean ±SD	47.46±21.0	23.58± 12.88	24±4.24
Median (range)	37.5(21-90)	20.5(4-60)	24(8-37)
Alkaline phosphatase (IU/L)				0.0108
Mean ±SD	190.42±42.59	181.96±41.12	127.6±12.02
Median (range)	179.5(134-300)	173(125-280)	128(111-145)
F. glucose (mg/dl)				0.57441
Mean ±SD	124.92±62.18	132.33±65.68	109±30.41
Median (range)	89(59-317)	114(60-369)	30.41(77-165)
AST/ALT ratio				0.169847
Mean ±SD	1.49±0.44	1.40±0.77	0.97±0.16
Median (range)	1.01(0.65-2.57)	1.36 (0.29-4.5)	0.99(0.69-1.22)
Fib-4 score				0.007
Mean ±SD	1.85±0.98	1.38±0.77	0.65±.30
Median (range)	1.59(0.58-4.12)	1.21(0.32-3.67)	0.58(0.32-1.07)
APRI				0.0003
Mean ±SD	0.6±0.35	0.29±0.19	0.29±0.18
Median (range)	0.46(0.18-1.3)	0.23(0.04-0.88)	0.26(0.16-0.51)

Significant; APRI: AST to platelet ratio index; fibrosis-4 index.